Get the Stockscreener App
47.30
0.19%
-0.09
After Hours:
47.30
Vaxcyte Inc stock is traded at $47.30, with a volume of 1.33M.
It is down -0.19% in the last 24 hours and down -22.22% over the past month.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
See More
Previous Close:
$47.39
Open:
$47.35
24h Volume:
1.33M
Relative Volume:
0.95
Market Cap:
$6.83B
Revenue:
-
Net Income/Loss:
$-766.63M
P/E Ratio:
-8.2908
EPS:
-5.7051
Net Cash Flow:
$-712.55M
1W Performance:
-9.72%
1M Performance:
-22.22%
6M Performance:
-1.00%
1Y Performance:
+39.32%
1-Day Range:
$47.00
$48.37
1-Week Range:
$46.39
$53.21
52-Week Range:
$29.08
$65.00
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
47.30 | 6.84B | 0 | -766.63M | -712.55M | -5.7051 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Reiterated | Needham | Buy |
| Sep-12-25 | Initiated | Goldman | Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-24 | Initiated | Goldman | Buy |
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
Vaxcyte stock (US92242T1016): clinical-stage vaccine developer draws attention after recent capital - AD HOC NEWS
Vaxcyte (PCVX) slips 3.8% as investors digest recent ownership filings and cash-burn outlook - Quiver Quantitative
Why Vaxcyte (PCVX) Is Down 9.7% After Steeper Q1 Losses And Accelerated R&D Spending - simplywall.st
Pfizer Expands Pneumococcal Vaccine Push With New Programs - Benzinga
Vaxcyte, Inc. (PCVX) Stock Analysis: Biotech Innovator With Over 100% Upside Potential - DirectorsTalk Interviews
Vaxcyte Inc stock (US92242T1016): fresh data from pneumococcal vaccine program keeps biotech in focu - AD HOC NEWS
Vaxcyte stock (US92242T1016): Pneumococcal vaccine data keeps investors focused - AD HOC NEWS
RA Capital reports 12.97M shares in Vaxcyte (NASDAQ: PCVX) - Stock Titan
Janus Henderson (PCVX) discloses 16.6M shares, 11.5% ownership - Stock Titan
Jones Hill Capital LP's Vaxcyte Inc(PCVX) Holding History - GuruFocus
(PCVX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
DIADEMA PARTNERS LP's Vaxcyte Inc(PCVX) Holding History - GuruFocus
TradingKey - TradingKey
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring a 105% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Vaxcyte, Inc. $PCVX Shares Sold by State of New Jersey Common Pension Fund D - MarketBeat
Nan Fung Trinity HK Ltd. Acquires 38,680 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Guggenheim Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $116 - Moomoo
PCVX Technical Analysis | Trend, Signals & Chart Patterns | VAXCYTE INC (NASDAQ:PCVX) - ChartMill
Vaxcyte Slides After Q1 Loss Widens as Spending Ramps Ahead of Key Phase 3 Readouts - Moomoo
Vaxcyte slides after Q1 loss widens as spending ramps ahead of key Phase 3 readouts - Quiver Quantitative
BofA Securities Maintains Vaxcyte(PCVX.US) With Buy Rating - Moomoo
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $75 - Moomoo
Vaxcyte Down Over 10%, On Track for Largest Percent Decrease Since May 2025 -- Data Talk - Moomoo
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update - Investing News Network
Higher Vaxcyte (NASDAQ: PCVX) Q1 loss as late-stage trials expand - Stock Titan
Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vaxcyte | 8-K: Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo
Vaxcyte (NASDAQ: PCVX) advances Phase 3 VAX-31 program and holds $2.7B cash - Stock Titan
FMR LLC discloses 11.4% stake in Vaxcyte (NASDAQ: PCVX) - Stock Titan
Vaxcyte | 10-Q: Q1 2026 Earnings Report - Moomoo
Vaxcyte (NASDAQ:PCVX) Stock Price Down 6.8%What's Next? - MarketBeat
Vaxcyte, Inc. (PCVX) Investor Outlook: Analyzing a 91% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
How (PCVX) Movements Inform Risk Allocation Models - Stock Traders Daily
Jennison Associates LLC Has $31.26 Million Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Insider Sell Alert: Jim Wassil Sells Shares of Vaxcyte Inc (PCVX) - GuruFocus
Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market - Seeking Alpha
Vaxcyte COO Jim Wassil sells $127,869 in PCVX shares By Investing.com - Investing.com Canada
Vaxcyte (NASDAQ:PCVX) COO Sells $127,867.50 in Stock - MarketBeat
Vaxcyte COO Jim Wassil sells $127,869 in PCVX shares - Investing.com
Vaxcyte (PCVX) COO Jim Wassil sells 2,250 shares in Rule 10b5-1 trade - Stock Titan
PCVX (PCVX) insider James Wassil files planned sales totaling $566,913.91 - Stock Titan
Vaxcyte Executive Compensation, Directors, and Corporate Governance Overview 2025 - Minichart
Universal Beteiligungs und Servicegesellschaft mbH Raises Stake in Vaxcyte, Inc. $PCVX - MarketBeat
Vanguard (PCVX) holds 7.25M Vaxcyte shares, reports 5.03% stake - Stock Titan
Pictet Asset Management Holding SA Has $40.67 Million Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte (PCVX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring the 83% Potential Upside in Vaccine Innovation - DirectorsTalk Interviews
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Vaxcyte launches proposed $500M public offering of stock, warrants - MSN
Vaxcyte Completes Enrollment for Phase 3 VAX-31 Vaccine Trials - HarianBasis.co
[ARS] Vaxcyte, Inc. SEC Filing - Stock Titan
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):